BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $251 | -16.6% | 3,684 | 0.0% | 0.01% | -18.2% |
Q2 2023 | $301 | -66.0% | 3,684 | -69.1% | 0.01% | -65.6% |
Q1 2023 | $884 | -10.4% | 11,913 | 0.0% | 0.03% | -11.1% |
Q4 2022 | $987 | -99.9% | 11,913 | +225.9% | 0.04% | -7.7% |
Q3 2022 | $1,038,000 | +227.4% | 3,655 | +299.9% | 0.04% | +225.0% |
Q2 2022 | $317,000 | +17.8% | 914 | +46.9% | 0.01% | +33.3% |
Q1 2022 | $269,000 | -14.3% | 622 | +2.5% | 0.01% | -18.2% |
Q4 2021 | $314,000 | -9.0% | 607 | -14.9% | 0.01% | -8.3% |
Q3 2021 | $345,000 | -2.8% | 713 | -9.6% | 0.01% | 0.0% |
Q2 2021 | $355,000 | +569.8% | 789 | +471.7% | 0.01% | +500.0% |
Q1 2021 | $53,000 | +20.5% | 138 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $44,000 | +29.4% | 138 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $34,000 | -5.6% | 138 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $36,000 | -87.3% | 138 | -90.8% | 0.00% | -87.5% |
Q1 2020 | $284,000 | -13.7% | 1,500 | 0.0% | 0.02% | +6.7% |
Q4 2019 | $329,000 | – | 1,500 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |